Adherium Ltd. · ASX:ADR
Adherium — JP Morgan Conference 2017
15 slides from Adherium's conference presentation, Jan 11, 2017
Slide 1: Adherium Company Presentation January 2017
For personal use only ADHERIUM Company Presentation January 2017 Garth Sutherland Group CEO
Slide 2: Forward Looking Statement
Forward Looking Statement For personal use only The following material is of a general nature and has only been prepared as a presentation aid. This presentation does NOT contain all of the information that may be required for evaluating Adherium Limited ACN 605 352 510 (Adherium® ), its assets, pro
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS Adherium provides valuable exposure to the rapidly growing digital health sector For personal use only Commercialisation stage digital health company with the most clinically proven solution in the respiratory space Valuable intellectual property portfolio, with a 15 year i
Slide 4: A Recognised Problem
A RECOGNISED PROBLEM Adherium understands non-adherence to preventative medication is the major cause of poorly-controlled asthma & COPD For personal use only The challenge of non-adherence The challenge of uncontrolled patients Non-adherence is defined as patients that might not Poorly-controlled p
Slide 5: Adherium's Smartinhaler Solution
ADHERIUM’S SMARTINHALER™ SOLUTION Proprietary technology and databases support a differentiated product range with proven results For personal use only Adherium’s Smartinhaler™ platform Smartinhaler™ digital health solution Proprietary electronic measurement device for respiratory market Tracks inha
Slide 6: Proprietary Technology
PROPRIETARY TECHNOLOGY Market proven proprietary technology positioning Adherium for scalable growth For personal use only Clinically proven, market ready Intellectual property Adherium’s Smartinhaler™ platform is the only product available for the Adherium has a valuable IP portfolio, comprising in
Slide 7: Clinically Proven Efficacy
CLINICALLY PROVEN EFFICACY Adherium’s Smartinhaler™ is the most clinically proven solution to improve patient outcomes For personal use only Four independent clinical trials prove that the use of the Adherium Smartinhaler™ leads to… 3.4 times More patients achieving 80% adherence to preventative med
Slide 8: Value Propositions
VALUE PROPOSITIONS Adherium improves the lives of people with asthma & COPD through real-time delivery of invaluable insights For personal use only Parents & Patients Caregivers Physicians Receive reminders and feedback on the Track children/elderly relatives behaviour Gain visibility on patie
Slide 9: AstraZeneca Partnership
ASTRAZENECA PARTNERSHIP Validating technology through initial commercial partnership with AstraZeneca For personal use only Partnership with AstraZeneca AstraZeneca product development and supply agreement In July 2015, Adherium entered into a long term partnership AstraZeneca currently purchases
Slide 10: Corporate
CORPORATE Adherium’s focus on revenue and market share growth in FY17 is enabled by a strong cash balance For personal use only Financial information Top shareholders2 Share price (31-Dec-16) A$0.24 One Funds Management Australian fund manager 13.9% Number of shares1 172.1m Fidelity International Gl
Slide 11: Board of Directors
BOARD OF DIRECTORS Entrepreneurial founder supported by an experienced Board and management team For personal use only Independent Non-Executive Chairman Founder of Adherium Thomas Lynch Mr Lynch has extensive capital markets experience and the internationalisation in the healthcare sector. Garth Su
Slide 12: Growth Opportunities
GROWTH OPPORTUNITIES Adherium is at the forefront of a large unmet market opportunity across multiple verticals For personal use only Future market opportunities Chronic respiratory disease First target market Adherium is also able to leverage its leadership in respiratory disease, and Adherium’s
Slide 13: Commercialisation Strategy
COMMERCIALISATION STRATEGY Adherium creates multiple additional revenue streams through our data monetization program For personal use only Data Revenue Streams Patients, Parents Payers & Pharmaceutical & Caregivers Providers Physicians Companies Researchers Value Personalized care Quantificatio
Slide 14: Positioning Adherium for Success
POSITIONING ADHERIUM FOR SUCCESS Adherium’s long term strategy is to become a global leader in digital health solutions For personal use only Sign full contract with US hospital network and fully integrate SmartInhaler™ products during FY2017 Payor/provider roll-out Transition to “Software as a
Slide 15: In Summary: An Unparalleled Opportunity
In Summary An Unparalleled Opportunity For personal use only Electronic monitoring and interventions will become the Revenues will be derived from a number of channels: chronic disease management standard Multinational pharmaceutical & medical technology We have tens of thousands of devices